Boehmeriasin A as new lead compound for the inhibition of topoisomerases and SIRT2
Two synthetic approaches to boehmeriasin A are described. A gram scale racemic preparation is accompanied by an efficient preparation of both the pure enantiomers using the conformationally stable 2-piperidin-2-yl acetaldehyde as starting material. The anti-proliferative activity in three cancer cel...
Saved in:
Published in | European journal of medicinal chemistry Vol. 92; pp. 766 - 775 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
ISSY-LES-MOULINEAUX
Elsevier Masson SAS
06.03.2015
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Two synthetic approaches to boehmeriasin A are described. A gram scale racemic preparation is accompanied by an efficient preparation of both the pure enantiomers using the conformationally stable 2-piperidin-2-yl acetaldehyde as starting material. The anti-proliferative activity in three cancer cell lines (CEM, HeLa and L1210) and two endothelial cell lines (HMEC-1, BAEC) indicates promising activity at the nanomolar range. Topoisomerases and SIRT2 are identified as biological targets and the experimental data has been supported by docking studies.
[Display omitted]
•We describe two synthetic approaches to the alkaloid boehmeriasin A.•Anti-proliferative activity in 5 cell lines indicates activity at the nanomolar range.•Topoisomerases and SIRT2 are identified as biological targets.•Experimental data are supported by docking studies. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0223-5234 1768-3254 |
DOI: | 10.1016/j.ejmech.2015.01.038 |